<?xml version='1.0' encoding='utf-8'?>
<document id="26081137"><sentence text="Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors." /><sentence text="4-{(R)-(3-Aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-N,N-diethylbenzamide (AZD2327) is a highly potent and selective agonist of the Î´-opioid receptor"><entity charOffset="0-85" id="DDI-PubMed.26081137.s2.e0" text="4-{(R)-(3-Aminophenyl)[4-(4-fluorobenzyl)-piperazin-1-yl]methyl}-N,N-diethylbenzamide" /><entity charOffset="87-94" id="DDI-PubMed.26081137.s2.e1" text="AZD2327" /><pair ddi="false" e1="DDI-PubMed.26081137.s2.e0" e2="DDI-PubMed.26081137.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26081137.s2.e0" e2="DDI-PubMed.26081137.s2.e1" /></sentence><sentence text=" AZD2327 and N-deethylated AZD2327 (M1) are substrates of cytochrome P450 3A (CYP3A4) and comprise a complex multiple inhibitory system that causes competitive and time-dependent inhibition of CYP3A4" /><sentence text=" The aim of the current work was to develop a physiologically based pharmacokinetic (PBPK) model to predict quantitatively the magnitude of CYP3A4 mediated drug-drug interaction with midazolam as the substrate"><entity charOffset="183-192" id="DDI-PubMed.26081137.s4.e0" text="midazolam" /></sentence><sentence text=" Integrating in silico, in vitro and in vivo PK data, a PBPK model was successfully developed to simulate the clinical accumulation of AZD2327 and its primary metabolite"><entity charOffset="16-22" id="DDI-PubMed.26081137.s5.e0" text="silico" /></sentence><sentence text=" The inhibition of CYP3A4 by AZD2327, using midazolam as a probe drug, was reasonably predicted"><entity charOffset="44-53" id="DDI-PubMed.26081137.s6.e0" text="midazolam" /></sentence><sentence text=" The predicted maximum concentration (Cmax) and area under the concentration-time curve (AUC) for midazolam were increased by 1" /><sentence text="75 and 2" /><sentence text="45-fold, respectively, after multiple dosing of AZD2327, indicating no or low risk for clinically relevant drug-drug interactions (DDI)" /><sentence text=" These results are in agreement with those obtained in a clinical trial with a 1" /><sentence text="4 and 1" /><sentence text="5-fold increase in Cmax and AUC of midazolam, respectively"><entity charOffset="35-44" id="DDI-PubMed.26081137.s12.e0" text="midazolam" /></sentence><sentence text=" In conclusion, this model simulated DDI with less than a two-fold error, indicating that complex clinical DDI associated with multiple mechanisms, pathways and inhibitors (parent and metabolite) can be predicted using a well-developed PBPK model" /><sentence text="" /></document>